SUMMARY Ten patients with active rheumatoid arthritis (RA) were entered into a pilot study to evaluate the effectiveness of thiomalic acid as a disease modifying agent and to assess its toxicity. Oral thiomalic acid (100 mg) was given daily for up to six months. Changes in disease activity were recorded monthly and all side effects noted. No patient recorded any improvement in subjective well being, pain score, or duration of early morning stiffness. No significant change occurred in articular index or haemoglobin (Hb); the erythrocyte sedimentation rate (ESR) showed a tendency to increase. Only three patients completed six months' treatment; six withdrew because of toxic reactions (three with rashes and three with severe gastrointestinal upset) and one because of lack of effect. Thiomalic acid alone appears to have no significant antirheumatic activity and is associated with an unacceptably high incidence of adverse reactions.
A number of thiol containing drugs, including D-penicillamine and disodium aurothiomalate, have been shown to be effective antirheumatic agents.1 2 Recent reporis suggest that at least part of their efficacy may depend upon specific actions of the sulphydryl group, in particular effects on intracellular oxidation status,3 reduced glutathione levels,4 and oxygen derived free radicals. 5 We have previously shown that immediately after intramuscular injection disodium aurothiomalate dissociates to form free thiomalate and protein bound gold. Preliminary data on a small number of patients published by Munthe and Jellum in 1980 suggested that sodium thiomalate, given orally, might be as effective and less toxic than disodium aurothiomalate. 6 We have, therefore, undertaken a pilot study to evaluate the clinical and laboratory changes that occur when patients with RA are treated with oral thiomalic acid.
Patients and methods
Ten patients were entered into the study. All had classical or definite RA according to the criteria of the American Rheumatism Association and had failed to respond to simple analgesics or nonAccepted for publication 14 September 1987. Correspondence to Dr S R Rudge, Rheumatology Department, Newham General Hospital, Glen Road, Plaistow, London E13 8SL.
steroidal anti-inflammatory drugs. None had received gold or penicillamine in the preceding six months and none was currently receiving steroids. The group consisted of six women and four men, mean age 56 3 years (range 36-64), and mean disease duration six years (range six months to 17 years). All patients were RA latex positive before the start of thiomalic acid therapy. The apparent lack of effect of thiomalate could be explained by poor absorption of the capsules or by the dose being too small. Absorption studies confirm that thiomalate was rapidly absorbed, reaching plasma levels comparable with those achieved after a single intramuscular dose of sodium aurothiomalate, provided that the capsule was taken on an empty stomach.9 The dose given amounted to 700 mg thiomalic acid weekly, 36 times that normally given by intramuscular injection in the form of disodium aurothiomalate. It is unlikely, therefore, that the dose was too small, and the development of side effects in six patients precluded any increase. We 
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